A Phase I Trial of ZIO-101 in Solid Tumors

NCT00591396 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2012-07-19

No results posted yet for this study

Summary

A Phase I Trial of ZIO-101 (Darinaparsin) in Solid Tumors

Conditions

Interventions

DRUG

ZIO-101 (Darinaparsin)

Dose Escalation of ZIO-101 (Darinaparsin) given daily for five consecutive days to be repeated every 28 days for up to six months

Sponsors & Collaborators

  • Alaunos Therapeutics

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-07-31
Primary Completion
2008-07-31
Completion
2008-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00591396 on ClinicalTrials.gov